FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * TOMSICEK MICHAEL JOHN 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)         (First)         (Middle)
C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
12/3/2019
(Street)
CAMBRIDGE, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units   (1) 12/3/2019    A     20000       (2)  (2) Common Shares  20000  $0.00  20000  D   

Explanation of Responses:
(1)  Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
(2)  The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
TOMSICEK MICHAEL JOHN
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE, MA 02139


Chief Financial Officer

Signatures
/s/ Michael Esposito, attorney-in-fact 12/5/2019
**Signature of Reporting Person Date
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more CRISPR Therapeutics Charts.
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more CRISPR Therapeutics Charts.